Transarterial chemoembolization combined with microwave ablation and apatinib in patients with Barcelona clinic liver cancer Stage C hepatocellular carcinoma: A propensity score matching analysis

Simple item page
dc.contributor.authorShuanggang, Chenen_US
dc.contributor.authorShen, Lujunen_US
dc.contributor.authorQiu, Zhiyuen_US
dc.contributor.authorQi, Hanen_US
dc.contributor.authorCao, Feien_US
dc.contributor.authorXie, Linen_US
dc.contributor.authorFan, Weijunen_US
dc.date.accessioned2020-11-18T10:08:17Z
dc.date.available2020-11-18T10:08:17Z
dc.date.issued2020-05
dc.description.abstractContext and Aims: Apatinib combined with transarterial chemoembolization (TACE) has shown promising results in cases of Barcelona clinic liver cancer Stage C (BCLC C) hepatocellular carcinoma (HCC). This study aimed to investigate the efficacy and safety of TACE in combination with microwave ablation (MWA) and apatinib. Materials and Methods: A retrospective, single.center study was undertaken using a one.to.one propensity score matching (PSM) analysis design and involved BCLC C HCC patients who underwent treatment with TACE.MWA.apatinib or TACE alone between January 2013 and June 2018. The patients were recommended to administer 500mg apatinib per day, combined with MWA and TACE. The adverse effects of apatinib, MWA. and TACE.related complications, progression.free survival (PFS), and overall survival (OS) were assessed. Results: Of the 149 patients with BCLC C HCC who underwent TACE.MWA.apatinib or TACE alone, 131 were included in our study. Among them, 21 (16.0%) received TACE.MWA.apatinib and 110 (84.0%) underwent TACE alone. After PSM, twenty pairs were enrolled into different treatment groups. Patients in the TACE.MWA.apatinib group had a significantly longer median PFS than patients in the TACE.alone group on both before (median, 8.9 vs. 1.7 months, P = 0.0002) and after PSM (median, 5.4 vs. 2.1 months, P = 0.001). They also had a significantly longer median OS than patients in the TACE.alone group on before (median, 24.4 vs. 5.8 months, P = 0.000007) and after PSM (median, 24.4 vs. 5.4 months, P = 0.00005). Conclusions: The combination of apatinib, TACE, and MWA in BCLC C HCC patients is safe and effective. Toxicity is manageable by adjusting the apatinib dosageen_US
dc.identifier.affiliationsDepartment of Minimally Invasive Interventional Therapy, Sun Yat-Sen University Cancer Center; Collaborative Innovation Center of Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-Sen University, Guangzhou, Chinaen_US
dc.identifier.affiliationsDepartment of Minimally Invasive Interventional Therapy, Sun Yat-Sen University Cancer Center; Collaborative Innovation Center of Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-Sen University, Guangzhou, Chinaen_US
dc.identifier.affiliationsCollaborative Innovation Center of Cancer Medicine, State Key Laboratory of Oncology in South China; Zhong Shan Medical School, Sun Yat-Sen University, Guangzhou, Chinaen_US
dc.identifier.affiliationsDepartment of Minimally Invasive Interventional Therapy, Sun Yat-Sen University Cancer Center; Collaborative Innovation Center of Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-Sen University, Guangzhou, Chinaen_US
dc.identifier.affiliationsDepartment of Minimally Invasive Interventional Therapy, Sun Yat-Sen University Cancer Center; Collaborative Innovation Center of Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-Sen University, Guangzhou, Chinaen_US
dc.identifier.affiliationsDepartment of Minimally Invasive Interventional Therapy, Sun Yat-Sen University Cancer Center; Collaborative Innovation Center of Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-Sen University, Guangzhou, Chinaen_US
dc.identifier.citationShuanggang Chen, Shen Lujun, Qiu Zhiyu, Qi Han, Cao Fei, Xie Lin, Fan Weijun. Transarterial chemoembolization combined with microwave ablation and apatinib in patients with Barcelona clinic liver cancer Stage C hepatocellular carcinoma: A propensity score matching analysis. Journal of Cancer Research and Therapeutics. 2020 May; 16(2): 250-257en_US
dc.identifier.issn0973-1482
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/213808
dc.languageenen_US
dc.publisherWolters Kluwer India Pvt. Ltd.en_US
dc.relation.issuenumber2en_US
dc.relation.volume16en_US
dc.source.urihttps://dx.doi.org//10.4103/jcrt.JCRT_345_19en_US
dc.subjectApatiniben_US
dc.subjectBarcelona clinic liver cancer Stage Cen_US
dc.subjecthepatocellular carcinomaen_US
dc.subjectmicrowave ablationen_US
dc.subjecttransarterial chemoembolizationen_US
dc.titleTransarterial chemoembolization combined with microwave ablation and apatinib in patients with Barcelona clinic liver cancer Stage C hepatocellular carcinoma: A propensity score matching analysisen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijcrt2020v16n2p250.pdf
Size:
1.09 MB
Format:
Adobe Portable Document Format
Download
Collections
Journal of Cancer Research and Therapeutics